Complex Coacervate for Controlled Release
Search text
Regenerative medicine
About 3 results
(0.10 seconds)
Controlled drug release scaffolds. What differentiates this technology is its capacity to deliver localized, controlled therapy while minimizing systemic exposure and associated risks. This system employs bioerodible polymer microparticles made from PLGA to enable the local, sustained release of a BMP type I receptor inhibitor such as dorsomorphin.
The tunable network provides a versatile platform that can be adapted for multiple therapeutic applications, including tissue regeneration and angiogenesis enhancement, making it a significant advancement compared to conventional delivery systems that often rely on toxic crosslinkers or less controllable release profiles. Adjustable gelation is achieved by tuning the heparin-to-nanoplatelet ratio and overall solid concentration, enabling controlled and sustained release of proteins such as FGF2. The system stands out due to its use of FDA-approved components and rapid, catalyst-free self-assembly, addressing key challenges in current protein delivery platforms.
This technology is distinguished by its multi-component approach that combines rapid in situ gelation with controlled, temporary porosity and balanced degradation. The reverse-gelling polymer enables minimally invasive delivery and immediate shape conformation, while the ECM enhances the natural regenerative response. - Minimally invasive injectable delivery for easy application.